Skip to Main Content

Paper Details

Exploration of baseline and early changes in neurocognitive characteristics as predictors of treatment response to bupropion, sertraline, and placebo in the EMBARC clinical trial.
Psychol Med
3
2022
Author NameAffiliation
Myrna M WeissmanNew York State Psychiatric Institute and Columbia University Vagelos College of Physicians and Surgeons
Ramin V ParseyStony Brook University
Melvin G McInnisUniversity of Michigan ann arbor
Diego A PizzagalliHarvard Medical School
Diego A PizzagalliCenter for Depression, McLean Hospital
Diego A PizzagalliMcLean Hospital
  • 1 - 6

Datasets

Release 1.2